What targeted therapies are used for people with the ALK mutation?

Learn more about lung cancer at http://www.YouAndLungCancer.com
Robert Winn, MD, director of Virginia Commonwealth University’s Massey Cancer Center, identifies crizotinib and alectinib as first-line targeted therapies for people with the ALK mutation, as well as second-line therapies ceritinib and brigatinib are additional targeted therapies if the earlier treatments do not work well.